<DOC>
	<DOCNO>NCT02815397</DOCNO>
	<brief_summary>Newly diagnose histologically confirm c-myc+ de novo DLBCL . Metformin 500 mg daily x 1 week , 500 mg twice daily ( BID ) x 2 week , 850 mg twice daily 1 month last cycle chemo-immunotherapy . DA-EPOCH-R every 21 day x 4 cycle ( CNS prophylaxis single triple therapy give intrathecally cycle patient deem appropriate treating physician ) . Restage 4 cycle CT . Complete remission partial remission : complete 2 cycle radiation therapy ( XRT ) consolidation per physician . Stable progressive disease go salvage therapy study .</brief_summary>
	<brief_title>DA-EPOCH-Rituximab/Metformin ( RM ) Double Hit Lymphoma</brief_title>
	<detailed_description>Subject admit in-patient care day 1 cycle discharge day 5 . On day 6 , subject receives Rituximab outpatient infusion facility . Metformin dispense day 1 cycle take follow : Cycle 1 day 1-7 500 mg daily . Days 8-21 , 500 mg twice daily . Cycle 2 end treatment , metformin give 850 mg twice daily . Inpatient treatment : DA-EPOCH every 21 day Etoposide ( VP-16 ) 50 mg/m2/d civi d1-4 ( continuous infusion ) Prednisone 60 mg/m2 BID po d1-5 Vincristine 0.4 mg/m2/d civi 1-4 ( continuous infusion ) Doxorubicin ( Adriamycin ) 10 mg/m2/d civi d1-4 ( continuous infusion ) Cyclophosphamide ( Cytoxan ) 750 mg/m2 IV 15 min d5 If clinically indicate , patient deem appropriate central nervous system ( CNS ) prophylaxis treat physician receive either single agent intrathecal methotrexate ( 12 mg ) triple therapy ( 15 mg methotrexate , 30 mg cytarabine , 30 mg hydrocortisone ) cycle chemotherapy . Rituximab 375 mg/m2 IV every 21 day D6-8 post DA-EPOCH ( per standard institutional guideline ) DA-dose adjustment paradigm base twice weekly complete blood count ( CBC ) ( dose adjustment start dos apply Etoposide ( VP-16 ) , Doxorubicin ( Adriamycin ) Cyclophosphamide ( Cytoxan ) . If nadir absolute neutrophil count ( ANC ) &gt; 500/microliter ( uL ) , 20 % increase 3 drug . If nadir &lt; 500/uL 1 2 measurement , dos last cycle . If nadir &lt; 500/uL least 3 measurement , nadir platelet &lt; 25,000/uL 1 measurement , 20 % decrease Etoposide , Doxorubicin Cyclophosphamide last cycle . Filgrastim ( Neupogen ) 5 mcg/kg sc qd begin d6 ANC &gt; 5,000/uL Pegfilgrastim ( Neulasta ) 6 mg sc 24-72 hour post chemotherapy . Restaging CT scan do cycle 4 : complete remission ( CR ) /partial remission ( PR ) - complete 2 cycle therapy OR consolidation radiation therapy per treat physician . stable disease ( SD ) /progressive disease ( PD ) - salvage therapy study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female ≥ 18 year age Diagnosis DLBCL document medical record histology base criterion establish World Health Organization subtyping require DLBCL cmyc+ define presence cmyc break karyotype/FISH and/or IHC ≥ 40 % ; include double hit ( bcl2 break find use cytogenetics/FISH ) and/or double expressors ( bcl2 protein expression ≥ 70 % IHC ) ; increase copy number consider positivity cmyc No prior therapy diagnosis DLBCL exception steroid Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 ( Appendix B ) Life expectancy least 6 month No history medication dependent diabetes mellitus No evidence acute chronic metabolic acidosis ( baseline venous lactate ≤ 4 ) Exclusion Criteria Patient already class antidiabetic medication include metformin , insulin analogue , sulfonylurea , thiazolidinediones ( TZDs ) incretinbased therapy clear need therapeutic intervention base fast blood glucose Known histological transformation indolent nonHodgkin Lymphoma ( iNHL ) chronic lymphocytic leukemia ( CLL ) aggressive form nonHodgkin 's lymphoma ( NHL ) ( ie , Richter transformation ) Burkitt and/or precursor lymphoblastic leukemia/lymphoma . Presence known intermediate highgrade myelodysplastic syndrome History active treat nonlymphoid malignancy within last 3 year exclude basal cell squamous cell skin cancer Evidence ongoing systemic bacterial , fungal , viral infection time start study drug . Subjects currently active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver involvement NHL stable chronic liver disease per investigator assessment ) Renal insufficiency creatinine &gt; 1.5 x upper limit normal ( ULN ) OR creatinine clearance &lt; 45 ml/min calculate CockcroftGault method CNS leptomeningeal involvement lymphoma HIV positive Ongoing inflammatory bowel disease Ongoing alcohol drug addiction Pregnancy breastfeed History prior allogeneic bone marrow progenitor cell solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Double Hit DLBCL</keyword>
</DOC>